Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘elanco’

Bayer completa la vendita della sua divisione Animal Health a Elanco

Posted by fidest press agency su lunedì, 10 agosto 2020

Alla firma dell’atto, Bayer ha ricevuto il pagamento di 5,17 miliardi di Dollari statunitensi (prima delle imposte) dopo la deduzione delle consuete rettifiche del prezzo di acquisto, oltre a 72,9 milioni di azioni di Elanco Animal Health, corrispondente al 15,5% delle azioni in circolazione dell’azienda statunitense. Bayer conferma la sua intenzione di cedere la quota in Elanco a tempo debito ma sicuramente a partire dalla metà del 2021 in avanti, periodo minimo di possesso delle azioni. La cessione del business Animal Health è la maggiore tra le dismissioni avviate da Bayer sin dal novembre 2018. L’azienda ha già completato la cessione dei marchi Coppertone™ e Dr. Scholl’s™ e del 60 per cento della sua partecipazione in Currenta, società di gestione servizi. Il business di Animal Health di Bayer conta circa 4.400 dipendenti e ha realizzato nel 2019 un fatturato di 1,57 miliardi di Euro. Sviluppa e commercializza prodotti e soluzioni innovative per la prevenzione e la cura delle malattie di animali d‘affezione e da reddito.

Posted in Economia/Economy/finance/business/technology | Contrassegnato da tag: , , | Leave a Comment »

Elanco Sells Victoria, PEI, Canada R&D Facility to The Center for Aquaculture Technologies Canada

Posted by fidest press agency su sabato, 28 dicembre 2019

Elanco Animal Health Incorporated (NYSE: ELAN) has signed an agreement to sell its Victoria, Prince Edward Island (PEI) aqua research and development facility to The Center for Aquaculture Technologies Canada, a leading aquaculture R&D and contract research services company with an established presence in PEI. The site was added to the Elanco footprint as part of the Novartis acquisition in 2015, and a source of innovative products and solutions to some of the industry’s greatest needs. Elanco will shift this important capability into its other existing R&D facilities.
“We are extremely grateful for the efforts, hard work and all contributions everyone at the Victoria R&D facility has made to the Elanco pipeline and the industry,” said Aaron Schacht, executive vice president of Innovation, Regulatory and Business Development at Elanco. “We are equally pleased to reach an outcome that keeps the site operational in the Victoria community with a group that values furthering the future of aquaculture.”John Buchanan, CEO of CATC, commented, “We are excited to continue to grow our aquaculture health and nutrition research services business in PEI, and have great plans for use of the facility.”In September, Elanco announced its decision to seek a buyer for the Victoria R&D site. Aquaculture and the company’s Charlottetown manufacturing facility continue to be a key component of Elanco’s growth, as evidenced by the company’s workforce expansion and capital investments at the site over the past two years.Today’s development is another step in Elanco’s journey to build an agile, stand-alone animal health company. These efforts build on the company’s productivity agenda, driving margin expansion through enhanced efficiency.The transaction is expected to close at the beginning of the first quarter in 2020. Financial terms of the deal were not disclosed.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »